Own stocks of companies that get drugs approved. That hasn’t been so easy. But the U.S. Food & Drug Administration (FDA) has ...

Three Fred Hutch Cancer Center researchers received a five-year, $3.8 million award from the National Cancer Institute to ...

Wilson celebrates the first U.S. patient to complete gene therapy for sickle cell, but says advocacy must continue.

In another sign of biopharma's waning interest in the traditional ex vivo gene therapy approach, CSL Behring is shutti | CSL ...

High-yield dividend stocks have been gaining momentum ahead of potential Fed rate cuts. While sticky inflation and possible ...

RNA vaccines saved lives during the COVID-19 pandemic, but older people had less of an immune response to the vaccines than did younger adults. Why? Boston Children's researchers, led by Byron Brook, ...

The inability of COVID vaccines to reach the long-lived plasma cell compartment in the bone marrow may explain their waning ...

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...

This transformative gift from Ted W. Love, M.D., and Joyce Y. Love will improve patient care for those with sickle cell ...

Centessa had recently conducted an interim analysis of a phase 2 study of its drug, called SerpinPC, which is designed to ...

The social campaign aimed to defy stigma, give voice to patients and care providers and pave the way for the launch of a ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...